# Gala Early Feasibility Study of RheOx

> **NCT03631472** · NA · UNKNOWN · sponsor: **Gala Therapeutics, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Chronic Bronchitis
- Copd Bronchitis

## Interventions

- **DEVICE:** RheOx

## Key facts

- **NCT ID:** NCT03631472
- **Lead sponsor:** Gala Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-06
- **Primary completion:** 2021-01-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03631472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03631472, "Gala Early Feasibility Study of RheOx". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03631472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*